Twice‐daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin‐naïve adults with Type 2 diabetes

AIM: To evaluate the efficacy and safety of twice‐daily insulin degludec/insulin aspart vs. twice‐daily biphasic insulin aspart 30 in people with Type 2 diabetes mellitus who were naïve to insulin. METHODS: In this 26‐week, multinational, open‐label, controlled, two‐arm, parallel‐group, treat‐to‐tar...

Descripción completa

Detalles Bibliográficos
Autores principales: Franek, E., Haluzík, M., Canecki Varžić, S., Sargin, M., Macura, S., Zacho, J., Christiansen, J. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063147/
https://www.ncbi.nlm.nih.gov/pubmed/26435365
http://dx.doi.org/10.1111/dme.12982

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063147/
https://www.ncbi.nlm.nih.gov/pubmed/26435365
http://dx.doi.org/10.1111/dme.12982

Ejemplares similares